Dose- and exposure response analysis of glycopyrrolate (GP) metered dose inhaler (MDI) to support optimal dosing in patients with COPD for combination product development Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Breaking microgram barrier to conduct dose ranging studies with long acting bronchodilators from a novel cosuspension metered dose inhaler product platform Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020
Formoterol provides comparable bronchodilatation when delivered via dry powder (DPI) and metered dose inhalers (MDI) in adult asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS) Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002
Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD Source: ERJ Open Res, 6 (2) 00187-2019; 10.1183/23120541.00187-2019 Year: 2020
Improvement in the drug delivery of salmeterol/fluticasone via a novel breath actuatedpressurized metered dose inhaler with a dose counter Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies Year: 2019
A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone Source: Eur Respir J 2001; 18: Suppl. 33, 53s Year: 2001
Objective measurement of inhalation profiles in patients using metered dose inhalers (MDIs) Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020
Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) delivered by a new soft mist inhaler (SMI) or a conventional metered dose inhaler (MDI) in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001
Systemic effects and pharmacokinetics of a new CFC-free metered dose inhaler of beclomethasone dipropionate following multiple dosing in asthmatic patients Source: Eur Respir J 2005; 26: Suppl. 49, 180s Year: 2005
Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator therapeutic response as that administered by the Rotahaler in adults with chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 125s Year: 2005
Asthma control with a breath-actuated pressurised metered dose inhaler (BAI) and prevalence of oral candidiasis: a prescribing claims study of 1701 patients prescribed a traditional pressurised metered dose inhaler (MDI) plus spacer or a BAI Source: Eur Respir J 2002; 20: Suppl. 38, 78s Year: 2002
Differences in patient perceived side effects (PPSE) of inhaled corticosteroids (ICS) between metered dose inhalers (MDI) and dry powder inhalers (DPI) Source: Eur Respir J 2003; 22: Suppl. 45, 474s Year: 2003
Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (MDI) in asthma patients Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001
Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg b.i.d. delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 311s Year: 2003
Pharmacokinetics (PK) of a single dose AZD7594 administered intravenously (IV), orally, and inhaled via two dry powder inhalers (DPI) and a pressurized metered-dose inhaler (pMDI) Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017
Comparison of systemic pharmacodynamic effects of two HFA formulations of formoterol fumarate delivered by pressurised metered dose inhaler in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Comparison of a formoterol multiple dose dry powder inhaler (MDPI) with a formoterol single dose dry powder inhaler (SDPI) in patients with moderate to severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 260s Year: 2004